Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. - Wikidata - awgldk - TriplyDB

Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.

Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.

http://www.wikidata.org/entity/Q33572430

about

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Managing anticoagulation for atrial fibrillation: current issues and future strategies Atrial fibrillation in women: treatment Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation Update on anti-coagulation in atrial fibrillation.Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Warfarin in atrial fibrillation patients with moderate chronic kidney disease Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation.Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study.Engaging with quality improvement in anticoagulation management.Should anticoagulation be resumed after intracerebral hemorrhage?Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants.New Stroke Prophylaxis Options in Atrial Fibrillation Patients.Preventative Measures of Stroke in Patients With Atrial Fibrillation.Prediction of stroke risk in atrial fibrillation, prevention of stroke in atrial fibrillation, and the impact of long-term monitoring for detecting atrial fibrillation.New avenues for anticoagulation in atrial fibrillation.Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.Biomarkers in atrial fibrillation: an overview.Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis.Assessment of Oral Anticoagulant Use in Residents of Long-Term Care Homes: Evidence for Contemporary Suboptimal Use.Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.The future landscape of anticoagulation management.Outcome of coumarin-therapy in an outpatient setting over a 10-year period: coumarin-therapy in clinical practice.The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation.Prediction Score for Anticoagulation Control Quality Among Older Adults.The value of time in therapeutic range in the prediction of outcomes at a populational level in patients treated with vitamin K antagonists.Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial.Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic.Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study.

P2860

Q24632951-4079896E-DBF3-492B-AC30-CB95E754B6D2 Q26991728-2C24F4D4-DCDE-4BEA-8A68-1F714875C1EF Q30241862-FD569769-E32E-4AB4-9136-1314BF5E3B30 Q33891646-B7F4260E-9093-4115-9854-62363498AB85 Q33978811-96DE9FAF-8C92-4C31-8172-9EA5B5C9C8E9 Q34297266-C81265CD-8DF6-434B-9E86-C09797A333A9 Q34633608-A05F95A3-E1AC-4952-82CC-3E4B9B160B20 Q34677974-3FB7C54B-A8B8-4989-98C8-8542504479B8 Q35172841-B84EF32C-A33C-4757-A44A-823B39692332 Q35353863-6F6EFFD7-F22D-4DD0-8C91-35379A99DF50 Q35752573-A02DBDF4-40C5-4AA0-B3B4-52662621A0A0 Q35985876-6A624F95-1677-40AD-AC33-7948C0E96C81 Q36017218-C24236B4-393A-4700-BFE6-756B82FBB177 Q36508477-90658A74-E4BE-4E74-B88E-622A773731CC Q36771378-A958958A-5778-4011-A517-56D7AEB079B7 Q36933765-F83BFE02-ECE1-4A1D-872A-414741383B14 Q37240690-59DF7305-54E5-4B6A-A4C2-40A58AA37B91 Q37310531-C4D8416E-5ED5-4368-BA65-5225D655011B Q37376804-27AC23BD-84F0-4687-9E39-3F0D147CB718 Q37495783-5AE17F9F-3BD1-48C5-A67F-CC75E239B6DE Q37495909-FA5E4D11-61F3-437A-9DCC-A8F4F4243C31 Q37496186-ED4B2524-7C23-4DF0-97BC-F255147E6B00 Q37885792-0348CB31-69F6-45F3-A08E-319FBE52936C Q38065063-6C5A08C3-177B-4394-AA82-71C6A1CBE35E Q38086125-E9519704-F3C0-47EF-8529-B4A517547188 Q38174213-804F1E7D-632B-4C4F-A14C-3361E692BC81 Q39000790-A7F12CE1-E529-4928-B911-BC524ADCC591 Q39458922-C76A92BE-DB5C-4C22-858B-EACB1D70166C Q41729803-03A55051-499F-4A92-9156-5A068E8D908D Q44797330-A9745CB2-15E3-4A26-816A-A604B5197DF3 Q45119524-D9694ABF-A7CC-4CDA-8B5C-108076F23D7E Q45883878-895118E6-09EB-4C1A-A3FC-CBD2937C59E0 Q47136092-0296052E-1722-4386-B0E5-00310FF27BDC Q48212557-975684A6-2419-4D8E-9493-9BC37F34A883 Q48378811-FC01C189-1FE2-4BA4-B092-7600AE6B90DA Q53103341-00EFBE07-165A-4630-8653-7E3A7B36C065 Q53151768-4233BB8F-842A-4D92-8437-1179D2A2DD93 Q55258970-F8890C49-5E89-42A4-8836-964D103909FF

P2860

Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.

http://www.wikidata.org/entity/Q33572430

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Should patient characteristics ...... ibrillation?: the ATRIA study.

@ast

Should patient characteristics ...... ibrillation?: the ATRIA study.

@en

Should patient characteristics ...... ibrillation?: the ATRIA study.

@nl

type

label

Should patient characteristics ...... ibrillation?: the ATRIA study.

@ast

Should patient characteristics ...... ibrillation?: the ATRIA study.

@en

Should patient characteristics ...... ibrillation?: the ATRIA study.

@nl

prefLabel

Should patient characteristics ...... ibrillation?: the ATRIA study.

@ast

Should patient characteristics ...... ibrillation?: the ATRIA study.

@en

Should patient characteristics ...... ibrillation?: the ATRIA study.

@nl

P1433

Q33572430-4C0D9119-C591-4908-A94E-C95938B37CF5

P1476

Q33572430-90794C93-0F06-461D-85D7-0F2DC24CAC2F

P2093

Q33572430-04A6C0E0-B39B-42B8-978F-4B81AEB6F763

Q33572430-4E573A00-3B8A-4DCA-823B-A216CE4E220E

Q33572430-860A1B09-C679-4832-8570-FCFC5391345D

Q33572430-929BA786-907A-4BDD-9E84-24B72180458E

Q33572430-95EC27F3-7243-4404-8C94-5D47AAFA42AF

Q33572430-A05181F3-B7BB-44A6-B708-A8BC8A5B5449

Q33572430-EAE719B4-08BB-4E9B-AFBA-16E971C2246E

P2860

Q33572430-0BD67F5A-4796-4F00-A197-ED049FFAA657

Q33572430-170DFC88-C728-41E4-835C-BC0C1AB030A5

Q33572430-1893FE0C-EA80-49C7-966F-CE00E1C6C590

Q33572430-1BF69A74-7BAE-42A9-B891-226F308C23DC

Q33572430-25E36DA7-C2B0-4C3F-9A65-3D5BA31DC96D

Q33572430-279FBF09-2EBC-44A5-B1BA-1BC057F5C712

Q33572430-2E44231E-438E-41A6-B651-17AB05C8F351

Q33572430-52EEBFF0-EF41-4D23-90BF-D2013FCEC5D7

Q33572430-68B739AF-1E2C-4A16-ACC5-A34DDEB1031D

Q33572430-6B95AF47-BA28-4072-9876-92F73344183E

P304

Q33572430-81FB53F8-0E2E-4CEF-B431-526D4B2F65EF

P31

Q33572430-3510AD24-653C-4DF4-A7BD-DD9D2D9DFE74

P356

Q33572430-707A12FC-2C3B-43AB-AC4D-95D498063537

P433

Q33572430-4E01ACC8-9A71-4C85-B611-C1BB8A31622E

P478

Q33572430-141EA261-7FDF-4FBF-A778-B64C55D109E0

P577

Q33572430-F229AE9C-39EE-44C2-8972-2B0052E458D9

P5875

Q33572430-65D1557F-3DE8-47D1-ADFD-A8018AA1BBCB

P698

Q33572430-D2C9CC1B-F22B-4A82-88D7-B2C1CF429472

P921

Q33572430-2CBD735F-BFAE-4F36-B4F4-7F0A91DF31A8

Q33572430-635862CB-511C-4EDC-B7CA-146C083D591C

Q33572430-E721343C-29DF-429A-9E24-7996F114043E

P932

Q33572430-924A5853-4714-4EEC-946A-E4C2C7780AFB

P356

CIRCOUTCOMES.108.830232

P1433

Circulation: Cardiovascular Quality and Outcomes

P1476

Should patient characteristics ...... ibrillation?: the ATRIA study.

@en

P2093

Alan S Go

http://www.w3.org/2001/XMLSchema#string

Daniel E Singer

http://www.w3.org/2001/XMLSchema#string

Leila H Borowsky

http://www.w3.org/2001/XMLSchema#string

Margaret C Fang

http://www.w3.org/2001/XMLSchema#string

Natalia Udaltsova

http://www.w3.org/2001/XMLSchema#string

Niela K Pomernacki

http://www.w3.org/2001/XMLSchema#string

Yuchiao Chang

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin

Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Validation of Clinical Classification Schemes for Predicting Stroke

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

P304

297-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCOUTCOMES.108.830232

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40767344

http://www.w3.org/2001/XMLSchema#string

P698

20031854

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

atrial fibrillation

P932

2801892

http://www.w3.org/2001/XMLSchema#string